2015 ACVIM Forum Research Abstract Program

Treatment with Protocol A was well tolerated; only two cats (n = 8) displayed adverse signs that required a decrease in dose of Exenatide. These clinical signs included anorexia (n = 2), and hypoglycemia (n = 1). During a12-hour BGC five cats experienced asymptomatic hypoglycemia (BG < 3.5), one on Protocol A, three on Protocol B, and one during both protocols (n = 8). Two cats (25%) went into diabetic remission during Protocol A (n = 8). The average change in the TDD of insulin from enrolment was 0.8 units (range-0-3 units); 0.9 units (range-0-3units) during Protocol A and 0.69 units (range-0-1units) during Protocol B. Three cats had a decrease in their insulin dose on Protocol A whereas only one cat had a decrease on Protocol B (n = 8). The fasting blood glucose was not significantly lower in cats receiving Protocol A versus Protocol B (P = 0.8). The average change in body weight of the cats was 0.6 kg. Seven cats (87.5%) lost weight on Protocol A (median= 0.66 kg, range-0.1-1.6 kg) and five (62.5%) cats gained weight on Protocol B (median-0.48 kg, range-0.14-1.14 kg). There was no significant difference in any of the hormone concentrations evaluated for cats on Protocol A versus B.